John Cassidy

ArsenalBiosciences, Inc., is a clinical stage programmable cell therapy company focused on the realization of solid tumor cell therapy to defeat cancer. Our discovery engine comprises precise CRISPR-enabled genome editing, integrated circuits incorporating logic gates for improved tumor targeting, and therapeutic enhancements enabling multiple pharmaceutical functions. With our programmable and computationally driven approach, we aim for enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. Our team is engineering living medicines to attack cancer’s inherent multi-faceted nature and bring dramatic improvements to the lives of patients.

ElevateBio is a technology-driven advanced therapy contract development and manufacturing organization (CDMO) powering the creation of life-transforming therapies. The company helps biopharmaceutical partners design, develop, and manufacture therapies from early discovery through commercialization. Combining proprietary gene editing tools and services, cGMP manufacturing capabilities, and industry-leading expertise, ElevateBio is enabling partners advance a breadth of therapeutic approaches and modalities including cell therapies, gene edited therapies, RNA therapies, mRNA vaccines, and more.

Neuron23™ Inc. is a leading clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The Company’s focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Founded in 2018, Neuron23 has assembled a world-class team of experts and entrepreneurs located in South San Francisco, CA.

CMR Surgical is a global medical devices company dedicated to transforming surgery with Versius®, a next-generation surgical robot. CMR is committed to working with surgeons, surgical teams and hospital partners, to provide an optimal tool to make robotic minimal access surgery universally accessible and affordable. With Versius, we are on a mission to redefine the surgical robotics market with practical, innovative technology and data that can improve surgical care. To find out more, or to join our world-class team please visit our website.

Proximie brings together telepresence, content management, and data insights to enable surgeons to share information and expertise, and improve patient safety.

Plexium is the premier, next-generation targeted protein degradation company, seeking to discover a wide range of monovalent target protein degraders that address the limitations of PROTACs and cereblon. The company’s platform is a proprietary drug discovery platform designed to identify novel small molecules that induce selective degradation of drug target proteins through E3 ligase mediated proteasomal degradation. From molecular glues to monovalent degraders, Plexium is advancing a pipeline of novel targeted protein degraders for the treatment of cancer, neurodegeneration, and other diseases.

At Ventus, we are pioneering a unique approach to structure-based drug discovery to address biologically validated, but difficult-to-drug targets. Others are building towards a future transformation of the drug development process … for Ventus, that future is already here. Our ReSOLVE™ platform integrates cutting-edge, structurally enabled, computational tools to identify and perfect new drug molecules for targets which have never been drugged or for which existing chemical matter leaves significant room for improvement. We are differentiated by our unique methods for modelling the properties of protein and water in motion. Optimal execution of these methods requires embedding our ReSOLVE platform with our world-class structural biology and chemistry teams. As our pipeline demonstrates, the ReSOLVE platform can find previously unknown pockets, better characterize known pockets, and solve the limitations of virtual screening, accelerating medicinal chemistry and structure-activity relationship (SAR) optimization. We are advancing a pipeline of new medicines to treat autoimmune and inflammatory diseases, neurological disorders, and cancer, and also generating a library of chemical matter for elusive targets for future pipeline needs and business development. Our team includes experienced biopharmaceutical executives, scientists who have delivered multiple approved medicines, and luminary academics spanning the fields of structural biology, immunology, and computational chemistry.

Leyden Labs aims to help people live their lives to the fullest. Our platform targets commonalities of viral families to protect humanity from known and future viruses. Our portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many variants of respiratory viruses, including ones in the influenza and coronavirus families. The Leyden Labs’ energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

Twelve Bio was acquired by Ensoma in February 2023. Ensoma is based out of Boston, MA, with a research facility and office in Copenhagen, Denmark. We are integrating Twelve Bio’s proprietary gene editing technology into Ensoma’s Engenious™ platform to move closer to our goal of developing one-time in vivo treatments that can precisely engineer specific cells to cure diseases from within. Learn more at www.ensoma.com.

Depixus® is pioneering a powerful new technology based on magnetic force spectroscopy, that reveals biomolecular interactions. MAGNA™ enables researchers to decode disease mechanisms and unlock a faster route to more effective therapies. Our MAGNA technology goes beyond decoding the static genetic code to reveal the dynamics of the genome that control health and disease.

STipe Therapeutics is a privately held biotechnology company with a vision to become a leader in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The Company was spun out from Aarhus University, Denmark in 2018 and concluded a EUR 20 million a Series A financing in September 2019. JOB RECRUITMENT SCAM ALERT STipe Therapeutics is aware of a job recruitment scam involving fraudulent human resources recruiters contacting job seekers. The scam includes requesting personal information, promising or requesting money to purchase office equipment, and interacting and conducting false interviews via social media platforms. Please note STipe Therapeutics does not utilize social media platforms to conduct formal job interviews or extend employment offers with job seekers. We encourage job seekers to be aware of this scam and remain vigilant while searching for a job with STipe Therapeutics.

In February, 2023 Imara merged with Enliven therapeutics (ELVN), with the resulting firm retaining Enliven’s name and development pipeline. Enliven is a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors to help patients with cancer live not only longer, but better.

ArsenalBiosciences, Inc., is a clinical stage programmable cell therapy company focused on the realization of solid tumor cell therapy to defeat cancer. Our discovery engine comprises precise CRISPR-enabled genome editing, integrated circuits incorporating logic gates for improved tumor targeting, and therapeutic enhancements enabling multiple pharmaceutical functions. With our programmable and computationally driven approach, we aim for enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. Our team is engineering living medicines to attack cancer’s inherent multi-faceted nature and bring dramatic improvements to the lives of patients.

ElevateBio is a technology-driven advanced therapy contract development and manufacturing organization (CDMO) powering the creation of life-transforming therapies. The company helps biopharmaceutical partners design, develop, and manufacture therapies from early discovery through commercialization. Combining proprietary gene editing tools and services, cGMP manufacturing capabilities, and industry-leading expertise, ElevateBio is enabling partners advance a breadth of therapeutic approaches and modalities including cell therapies, gene edited therapies, RNA therapies, mRNA vaccines, and more.

Neuron23™ Inc. is a leading clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The Company’s focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Founded in 2018, Neuron23 has assembled a world-class team of experts and entrepreneurs located in South San Francisco, CA.

CMR Surgical is a global medical devices company dedicated to transforming surgery with Versius®, a next-generation surgical robot. CMR is committed to working with surgeons, surgical teams and hospital partners, to provide an optimal tool to make robotic minimal access surgery universally accessible and affordable. With Versius, we are on a mission to redefine the surgical robotics market with practical, innovative technology and data that can improve surgical care. To find out more, or to join our world-class team please visit our website.

Proximie brings together telepresence, content management, and data insights to enable surgeons to share information and expertise, and improve patient safety.